The careful gathering of women’s health science
Peptide therapy, decoded for women.
Editorial comparisons of peptide telehealth providers — credentials, pharmacy sourcing, pricing, states served — evaluated for women. Plus a free guide to bring to your first consult.
Every claim cited — studies, FDA documents, trial registries
Independent ratings · zero paid placements
Regulatory status dated on every entry
Compared. Six published criteria · zero paid placement. Editorial ratings come from the criteria — never from commercial relationships.
The 2026 moment
A different peptide conversation is finally possible.
April’s Category 2 revisions reshaped the regulated peptide landscape mid-stream, and July’s PCAC review moved it again. This is the first year a careful editorial layer for women is both useful and necessary — and that’s the work.
Why women come here
We read the internet so you don’t have to.
PubMed, FDA filings, peer-reviewed journals, the long tail of women’s-health writing — aggregated, dated, and trimmed to what actually helps you make a decision. Four things you get here that a Google search won’t give you.
- 01
We did the reading
Hundreds of studies, FDA filings, and peer-reviewed papers — aggregated, dated, and organized around the question that brought you here (perimenopause, libido, skin, sleep, recovery, metabolic). You arrive informed, not exhausted from scrolling.
vs. Google: Google gives you ten generic articles ranked by SEO. None of them written for a woman.
- 02
Calibrated evidence vocabulary
Preclinical · limited clinical · multiple human studies · Phase 3 · FDA-approved. Each word means a specific thing, and we use them precisely on every entry.
vs. Google: Google says "studies show." We tell you whose body the study was in.
- 03
Regulatory clarity, post-April
April 2026 removed twelve peptides from FDA Category 2 — with a July 2026 PCAC review still scheduled. Both events flagged on every peptide page, with the FDA-approved exceptions separately marked.
vs. Google: Top Google hits are still telling you BPC-157 is banned. The picture changed in April.
- 04
Tools you can print
A twelve-question consult checklist with handwriting space. A provider scorecard. A one-page evidence chart. Designed for the consult itself, not just the read.
vs. Google: Google gives you information you read once and forget by Friday.
Start where you are
If your goal is X, the peptides worth knowing.
Six entry-points into the catalog — the peptides actually researched for each goal, with the FDA and evidence layer attached. Pick the one that brought you here.
Peptide in focus
Sermorelin
CompoundedHormone & GH-axisA GHRH analog with the longest clinical history of any GH-axis peptide. Currently compoundable in the U.S. (a separate regulatory status from the Category 2 group). Relevant to women for body composition, sleep, and recovery in midlife.
Latest writing
New and recently updated.
- metabolic7 min
GLP-1 and Hair Loss in Women: What the Ads Get Backwards
Instagram ads increasingly pair GLP-1 medications with hair benefits. The evidence points the other way — GLP-1s are associated with hair loss, and the risk is higher in women. What's actually happening, why, and what to do about it.
- metabolic10 min
GLP-1 Medications for Women: What the Research Actually Says
A grounded look at GLP-1 medications — semaglutide, tirzepatide, and the newer agents in trials — for women specifically: what the 2026 evidence shows, the muscle-and-bone question, the sourcing and regulatory picture, and what these drugs do not do.
- skin7 min
Do Peptide Serums Actually Work? Your Skincare Peptides, Graded
Peptide serums are one of the biggest skincare categories sold to women — but the 2026 evidence is more complicated than the marketing. The penetration problem, why oral may beat topical, and an honest grade of the peptides in your serum.
Editorially evaluated
Where to start your search.
Peptide-telehealth providers we've evaluated for women — based on credentials, pharmacy sourcing, pricing, and states served. Editorial ratings come from those criteria alone, never from commercial relationships.
Affiliate disclosure: Some links on this page are affiliate links. If you sign up with a provider after clicking, Anthivera may receive a referral fee at no additional cost to you. Editorial ratings reflect our judgment, not commercial relationships. Read the full disclosure.
Solace MD
4.6/5Higher price band, faster shipping, more personal care — the right fit if cost isn't the primary constraint.
- Price
- $110–$340/mo
- States
- 7 served
Read the reviewVisit siteEvergreen Women's Health
4.5/5Strongest fit for perimenopausal women seeking continuity of care — pairs hormone testing with peptide protocols.
- Price
- $89–$249/mo
- States
- 10 served
Read the reviewVisit siteNorthstar Peptide Co.
4.2/5Specialty: recovery and skin peptides. Less hormone-focused than competitors, but a tighter, more specialized catalog.
- Price
- $75–$220/mo
- States
- 8 served
Read the reviewVisit siteCanopy Telehealth Clinic
4.0/5Broad catalog and broad geographic reach; longer intake process but thorough lab work.
- Price
- $99–$299/mo
- States
- 12 served
Read the reviewVisit site
Join Anthivera Insider.
One careful, research-backed email a week on peptide therapy for women. No hype. Unsubscribe anytime.
The middle is harder — reading the trials, dating the regulatory status, saying “limited” out loud when the data is limited. — The Anthivera editors